OR WAIT null SECS
Biotech company hopes to tackle challenges surrounding therapeutics
Akron Bio, a biotech firm that aims to drive advanced therapy development through the manufacturing and commercialization of ancillary materials, has launched a new, state-of-the-art current good manufacturing practice (cGMP) plasmid DNA (pDNA) manufacturing facility in Sarasota, FL.
The company’s Sarasota facility will address critical demands in the rapidly growing gene therapy and vaccine markets by providing pDNA, an ancillary material used in the manufacture of advanced therapies. The new site—Akron Bio notes—will support an increasing clinical development pipeline by relieving and securing industry supply. The firm will also be doubling its Sarasota workforce to more than 100 by the end of this year, with plans to expand in the future in order to meet the growing customer demand.
“At Akron Bio, we are highly motivated by the lasting impact that cell and gene therapies, and vaccine treatments, have on patients’ lives,” says Robert Wedinger, CEO of Akron Bio. “This new facility will allow us to continue to drive the industry forward, while ensuring the highest quality and safety standards.”